Further evaluation of its anti-inflammatory abilities in vivo revealed that OIR3 exhibited therapeutic effects by inhibiting oxazolone-induced skin inflammation via inhibition of TNF-α, IL-1β and IL-6 mRNA expression. The gene discussed is IL6; the disease is dermatitis.